*Corresponding Author E-mail: super_tasbaha@mail.ru
This study aimed to explore the mechanistic links between COVID-19 and ocular disorders. The study sought to identify specific diseases, assess the effectiveness of treatment approaches, and provide insights into the broader implications for patient care.
We conducted a systematic search of PubMed and Medline databases, collecting relevant studies until June 2023. A rigorous PRISMA-based selection process ensured high-quality research inclusion. Bias risk assessment followed Cochrane's "Systematic Reviews of Interventions" guidelines. Five studies were selected for meta-analysis using Review Manager with a fixed-effects model, and heterogeneity was assessed.
Our analysis revealed substantial heterogeneity in ocular presentations post-COVID-19 infection (p<0.00001; I^2=97%). Notable findings included vision improvement in patients treated with oral steroids and intravenous methylprednisolone, as well as resolution of uveitis through cycloplegic and topical steroids.
This study sheds light on a lesser-explored facet of COVID-19, highlighting ocular disorders as potential viral symptoms. It contributes novel treatment insights and underscores the importance of considering ocular health in COVID-19 patient care.
Ocular disorders post-COVID-19 infection warrant attention from clinicians and researchers. Further investigations are essential to refine treatment strategies and improve the overall care of COVID-19 patients. Recognizing the ocular dimension of this viral illness is crucial for a holistic approach to healthcare delivery in the post-pandemic era.
Oral steroids in ocular treatment, Uveitis management post-COVID, Pharmacotherapy for COVID-19 ocular effects
